Cargando…

Polycaprolactone scaffold engineered for sustained release of resveratrol: therapeutic enhancement in bone tissue engineering

Biomaterials-based three-dimensional scaffolds are being extensively investigated in bone tissue engineering. A potential scaffold should be osteoconductive, osteoinductive, and osteogenic for enhanced bone formation. In this study, a three-dimensional porous polycapro-lactone (PCL) scaffold was eng...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamath, Manjunath Srinivas, Ahmed, Shiek SSJ, Dhanasekaran, M, Santosh, S Winkins
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875521/
https://www.ncbi.nlm.nih.gov/pubmed/24399875
http://dx.doi.org/10.2147/IJN.S49460
_version_ 1782297368835653632
author Kamath, Manjunath Srinivas
Ahmed, Shiek SSJ
Dhanasekaran, M
Santosh, S Winkins
author_facet Kamath, Manjunath Srinivas
Ahmed, Shiek SSJ
Dhanasekaran, M
Santosh, S Winkins
author_sort Kamath, Manjunath Srinivas
collection PubMed
description Biomaterials-based three-dimensional scaffolds are being extensively investigated in bone tissue engineering. A potential scaffold should be osteoconductive, osteoinductive, and osteogenic for enhanced bone formation. In this study, a three-dimensional porous polycapro-lactone (PCL) scaffold was engineered for prolonged release of resveratrol. Resveratrol-loaded albumin nanoparticles (RNP) were synthesized and entrapped into a PCL scaffold to form PCL-RNP by a solvent casting and leaching method. An X-ray diffraction study of RNP and PCL-RNP showed that resveratrol underwent amorphization, which is highly desired in drug delivery. Furthermore, Fourier transform infrared spectroscopy indicates that resveratrol was not chemically modified during the entrapment process. Release of resveratrol from PCL-RNP was sustained, with a cumulative release of 64% at the end of day 12. The scaffold was evaluated for its bone-forming potential in vitro using human bone marrow-derived mesenchymal stem cells for 16 days. Alkaline phosphatase activity assayed on days 8 and 12 showed a significant increase in activity (1.6-fold and 1.4-fold, respectively) induced by PCL-RNP compared with the PCL scaffold (the positive control). Moreover, von Kossa staining for calcium deposits on day 16 showed increased mineralization in PCL-RNP. These results suggest PCL-RNP significantly improves mineralization due to its controlled and prolonged release of resveratrol, thereby increasing the therapeutic potential in bone tissue engineering.
format Online
Article
Text
id pubmed-3875521
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-38755212014-01-07 Polycaprolactone scaffold engineered for sustained release of resveratrol: therapeutic enhancement in bone tissue engineering Kamath, Manjunath Srinivas Ahmed, Shiek SSJ Dhanasekaran, M Santosh, S Winkins Int J Nanomedicine Original Research Biomaterials-based three-dimensional scaffolds are being extensively investigated in bone tissue engineering. A potential scaffold should be osteoconductive, osteoinductive, and osteogenic for enhanced bone formation. In this study, a three-dimensional porous polycapro-lactone (PCL) scaffold was engineered for prolonged release of resveratrol. Resveratrol-loaded albumin nanoparticles (RNP) were synthesized and entrapped into a PCL scaffold to form PCL-RNP by a solvent casting and leaching method. An X-ray diffraction study of RNP and PCL-RNP showed that resveratrol underwent amorphization, which is highly desired in drug delivery. Furthermore, Fourier transform infrared spectroscopy indicates that resveratrol was not chemically modified during the entrapment process. Release of resveratrol from PCL-RNP was sustained, with a cumulative release of 64% at the end of day 12. The scaffold was evaluated for its bone-forming potential in vitro using human bone marrow-derived mesenchymal stem cells for 16 days. Alkaline phosphatase activity assayed on days 8 and 12 showed a significant increase in activity (1.6-fold and 1.4-fold, respectively) induced by PCL-RNP compared with the PCL scaffold (the positive control). Moreover, von Kossa staining for calcium deposits on day 16 showed increased mineralization in PCL-RNP. These results suggest PCL-RNP significantly improves mineralization due to its controlled and prolonged release of resveratrol, thereby increasing the therapeutic potential in bone tissue engineering. Dove Medical Press 2013-12-23 /pmc/articles/PMC3875521/ /pubmed/24399875 http://dx.doi.org/10.2147/IJN.S49460 Text en © 2014 Kamath et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Kamath, Manjunath Srinivas
Ahmed, Shiek SSJ
Dhanasekaran, M
Santosh, S Winkins
Polycaprolactone scaffold engineered for sustained release of resveratrol: therapeutic enhancement in bone tissue engineering
title Polycaprolactone scaffold engineered for sustained release of resveratrol: therapeutic enhancement in bone tissue engineering
title_full Polycaprolactone scaffold engineered for sustained release of resveratrol: therapeutic enhancement in bone tissue engineering
title_fullStr Polycaprolactone scaffold engineered for sustained release of resveratrol: therapeutic enhancement in bone tissue engineering
title_full_unstemmed Polycaprolactone scaffold engineered for sustained release of resveratrol: therapeutic enhancement in bone tissue engineering
title_short Polycaprolactone scaffold engineered for sustained release of resveratrol: therapeutic enhancement in bone tissue engineering
title_sort polycaprolactone scaffold engineered for sustained release of resveratrol: therapeutic enhancement in bone tissue engineering
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875521/
https://www.ncbi.nlm.nih.gov/pubmed/24399875
http://dx.doi.org/10.2147/IJN.S49460
work_keys_str_mv AT kamathmanjunathsrinivas polycaprolactonescaffoldengineeredforsustainedreleaseofresveratroltherapeuticenhancementinbonetissueengineering
AT ahmedshiekssj polycaprolactonescaffoldengineeredforsustainedreleaseofresveratroltherapeuticenhancementinbonetissueengineering
AT dhanasekaranm polycaprolactonescaffoldengineeredforsustainedreleaseofresveratroltherapeuticenhancementinbonetissueengineering
AT santoshswinkins polycaprolactonescaffoldengineeredforsustainedreleaseofresveratroltherapeuticenhancementinbonetissueengineering